- Molecular NameNorethindrone
- SynonymNA
- Weight298.426
- Drugbank_IDDB00717
- ACS_NO68-22-4
- Show 3D model
- LogP (experiment)2.97
- LogP (predicted, AB/LogP v2.0)2.79
- pkaN/A
- LogD (pH=7, predicted)2.79
- Solubility (experiment)0.00704 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-4.35
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors1
- No.of HBond Acceptors2
- No.of Rotatable Bonds1
- TPSA37.3
- StatusFDA approved
- AdministrationN/A
- PharmacologyA molecule used in some combined oral contraceptive pills and in some progestogen only pills. It is a progestogen and can be used to treat premenstrual syndrome, painful periods, abnormal heavy bleeding, irregular periods, menopausal syndrome (in combination with oestrogen), or to postpone a period. Norethindrone was the first orally highly active progestin to be synthesized.
- Absorption_value100.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability64.0
- Protein binding97.71
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life7 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboem-bolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, hypercholesterolemia, obesity and diabetes.
- LD50 (rat)N/A
- LD50 (mouse)N/A